Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry J M Groen

Showing results (141-150 of 274) with videos related to

Pageof 28
Sort By:
Lung Cancer (Amsterdam, Netherlands)|July 16, 2013
Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patientsMarlies E Heuvers, Femke Muskens, Koen Bezemer, et al.
British Journal of Pharmacology|June 14, 2005
New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kineticsJoost Bart, Eli C F Dijkers, Theodora D Wegman, et al.
Cancers|July 24, 2021
A Nationwide Study on the Impact of Routine Testing for <i>EGFR</i> Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on <i>EGFR</i> Mutation SubclassesBart Koopman, Betzabel N Cajiao Garcia, Chantal C H J Kuijpers, et al.
JTO Clinical and Research Reports|May 20, 2022
Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With <i>BRAF</i>-Mutated Advanced NSCLCBruce E Johnson, Christina S Baik, Julien Mazieres, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2023
Risk factors for cognitive impairment in radically treated stage III NSCLC: Secondary findings of the NVALT-11 studyHaiyan Zeng, Lizza E L Hendriks, Willem J A Witlox, et al.
Molecular Oncology|August 27, 2021
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitorsPaul van der Leest, Birgitta Hiddinga, Anneke Miedema, et al.
Plos One|April 6, 2016
Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome SequencingAli Saber, Anthonie J van der Wekken, Klaas Kok, et al.
European Radiology|March 20, 2013
Optimisation of volume-doubling time cutoff for fast-growing lung nodules in CT lung cancer screening reduces false-positive referralsMarjolein A Heuvelmans, Matthijs Oudkerk, Geertruida H de Bock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2019
Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer PatientsPauline L de Goeje, Myrthe Poncin, Koen Bezemer, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2016
Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinibVivian E M van den Boogaart, Quido G de Lussanet, Ruud M A Houben, et al.
Pageof 28

Showing results (141-150 of 274) with videos related to

Sort By:
Pageof 28
Lung Cancer (Amsterdam, Netherlands)|July 16, 2013
Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patientsMarlies E Heuvers, Femke Muskens, Koen Bezemer, et al.
British Journal of Pharmacology|June 14, 2005
New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kineticsJoost Bart, Eli C F Dijkers, Theodora D Wegman, et al.
Cancers|July 24, 2021
A Nationwide Study on the Impact of Routine Testing for <i>EGFR</i> Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on <i>EGFR</i> Mutation SubclassesBart Koopman, Betzabel N Cajiao Garcia, Chantal C H J Kuijpers, et al.
JTO Clinical and Research Reports|May 20, 2022
Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With <i>BRAF</i>-Mutated Advanced NSCLCBruce E Johnson, Christina S Baik, Julien Mazieres, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2023
Risk factors for cognitive impairment in radically treated stage III NSCLC: Secondary findings of the NVALT-11 studyHaiyan Zeng, Lizza E L Hendriks, Willem J A Witlox, et al.
Molecular Oncology|August 27, 2021
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitorsPaul van der Leest, Birgitta Hiddinga, Anneke Miedema, et al.
Plos One|April 6, 2016
Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome SequencingAli Saber, Anthonie J van der Wekken, Klaas Kok, et al.
European Radiology|March 20, 2013
Optimisation of volume-doubling time cutoff for fast-growing lung nodules in CT lung cancer screening reduces false-positive referralsMarjolein A Heuvelmans, Matthijs Oudkerk, Geertruida H de Bock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2019
Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer PatientsPauline L de Goeje, Myrthe Poncin, Koen Bezemer, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2016
Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinibVivian E M van den Boogaart, Quido G de Lussanet, Ruud M A Houben, et al.
Pageof 28